Astex Pharmaceuticals to Present at World Epigenetics Summit on December 8th
DUBLIN, Calif.--(BUSINESS WIRE)--Astex Pharmaceuticals, Inc. (NASDAQ: ASTX), a pharmaceutical company dedicated to the discovery and development of novel therapeutics, today announced that Tom Heightman, Ph.D., director, medicinal chemistry, will co-chair and present at the 2nd World Epigenetics Summit: Unlocking the Commercial and Therapeutic Potential of Epigenetics Research on December 6 to 8, 2011 in Munich.
Dr. Heightman’s presentation will occur on Dec 8th at 4:20 pm CET. He will discuss the Pyramid™ fragment-based drug discovery platform and its application towards epigenetic targets, and the current development of SGI-110, the Company’s second generation DNA hypomethylating agent. SGI-110 is a follow on to Astex Pharmaceuticals’ marketed product, Dacogen® (decitabine) for Injection, and is currently in a phase 1-2 clinical trial in myelodysplastic syndromes and acute myeloid leukemia patients. The Company is working with several cancer centers and the Stand Up to Cancer Epigenetics Dream Team on SGI-110.
About Astex Pharmaceuticals
Astex Pharmaceuticals is dedicated to the discovery and development of novel therapeutics with a focus on oncology. The Company is developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. Astex Pharmaceuticals, formerly SuperGen, developed Dacogen® (decitabine) for Injection and receives significant royalties on global sales.
For more information about Astex Pharmaceuticals, Inc., please visit http://www.astx.com.